The EPHX2 antibody is a research tool designed to target the enzyme epoxide hydrolase 2 (EPHX2), also known as soluble epoxide hydrolase (sEH). EPHX2 is a bifunctional enzyme with hydrolase and phosphatase activity, primarily involved in the metabolism of epoxy fatty acids, such as epoxyeicosatrienoic acids (EETs). These lipid mediators play critical roles in regulating vascular tone, inflammation, and cellular signaling. By hydrolyzing EETs into less active diols, EPHX2 modulates their bioavailability and physiological effects, linking it to cardiovascular diseases, metabolic disorders, and neurodegenerative conditions.
Antibodies against EPHX2 are widely used to study its expression, localization, and function in tissues and cell types. They enable detection via techniques like Western blotting, immunohistochemistry, and ELISA, aiding in understanding EPHX2's role in disease pathways. Research highlights EPHX2 as a therapeutic target, as its inhibition enhances EET levels, offering potential benefits in hypertension, diabetes, and pain management. The antibody's specificity is validated across species, including human, mouse, and rat models, supporting translational studies.
Developed for both basic and clinical research, EPHX2 antibodies contribute to drug discovery efforts, biomarker identification, and mechanistic studies, underscoring their importance in exploring lipid-mediated signaling and therapeutic interventions.